Alex Barnes1, Richard J Woodman2, Paul Kleinig3, Michael Briffa3, Timothy To3, Alan J Wigg1,4. 1. Hepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Adelaide, Australia. 2. Department of Epidemiliology and Biostatistics, College of Medicine and Public Health, Flinders University of South Australia, Australia. 3. Southern Adelaide Palliative Care Services, Australia. 4. College of Medicine and Public Health, Flinders University of South Australia, Australia.
Abstract
BACKGROUND AND AIMS: Palliative care referral for end stage liver disease (ESLD) is uncommon and usually occurs late. We aimed to review the rate of early palliative care referral (EPCR) in ESLD patients, its associations, and its impacts on resource utilisation and survival. METHODS: A retrospective review of all patients with ESLD admitted to a single hepatology unit between 2013 and 2016. Inclusion criteria for study entry were at least two admissions for decompensated liver disease within a six month period and not eligible for liver transplantation. The EPCR group was defined as those patients who received palliative care referral at least 30 days prior to mortality. RESULTS: 74 patients were included in the study. EPCR rate was 19%. On multivariate analysis EPCR was associated with hepatocellular carcinoma (OR 4.47, 95% CI 1.02-19.5, p=0.047), and negatively associated with alcoholic liver disease (OR 0.16, 95% CI 0.032-0.88 p=0.035). There was no difference in survival based on EPCR status. Hospitalization costs were lower in the EPCR group (p=0.027). There was also a significantly lower number of endoscopies (p=0.009), and blood transfusions (p=0.001) in the EPCR group. EPCR was also associated with higher rates of outpatient palliative care and advanced care planning. CONCLUSIONS: EPCR in ESLD was uncommon and associated with hepatocellular carcinoma and lack of alcoholic liver disease. EPCR was associated with decreased resource utilisation and further high quality studies are required to confirm the benefits of EPCR in ESLD. This article is protected by copyright. All rights reserved.
BACKGROUND AND AIMS: Palliative care referral for end stage liver disease (ESLD) is uncommon and usually occurs late. We aimed to review the rate of early palliative care referral (EPCR) in ESLDpatients, its associations, and its impacts on resource utilisation and survival. METHODS: A retrospective review of all patients with ESLD admitted to a single hepatology unit between 2013 and 2016. Inclusion criteria for study entry were at least two admissions for decompensated liver disease within a six month period and not eligible for liver transplantation. The EPCR group was defined as those patients who received palliative care referral at least 30 days prior to mortality. RESULTS: 74 patients were included in the study. EPCR rate was 19%. On multivariate analysis EPCR was associated with hepatocellular carcinoma (OR 4.47, 95% CI 1.02-19.5, p=0.047), and negatively associated with alcoholic liver disease (OR 0.16, 95% CI 0.032-0.88 p=0.035). There was no difference in survival based on EPCR status. Hospitalization costs were lower in the EPCR group (p=0.027). There was also a significantly lower number of endoscopies (p=0.009), and blood transfusions (p=0.001) in the EPCR group. EPCR was also associated with higher rates of outpatient palliative care and advanced care planning. CONCLUSIONS: EPCR in ESLD was uncommon and associated with hepatocellular carcinoma and lack of alcoholic liver disease. EPCR was associated with decreased resource utilisation and further high quality studies are required to confirm the benefits of EPCR in ESLD. This article is protected by copyright. All rights reserved.
Entities:
Keywords:
cirrhosis; end stage liver disease; palliative care
Authors: Jeffrey B Ames; Maya Djerboua; Norah A Terrault; Christopher M Booth; Jennifer A Flemming Journal: Can J Gastroenterol Hepatol Date: 2022-03-09
Authors: Jan C DeNofrio; Manisha Verma; Andrzej S Kosinski; Victor Navarro; Tamar H Taddei; Michael L Volk; Marie Bakitas; Kavitha Ramchandran Journal: Hepatol Commun Date: 2021-10-31
Authors: Lisa X Deng; Dorothea S Kent; David L O'Riordan; Steven Z Pantilat; Jennifer C Lai; Kara E Bischoff Journal: J Palliat Med Date: 2021-08-03 Impact factor: 2.947